{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:10:41Z","timestamp":1789132241772,"version":"build-2803163510"},"reference-count":153,"publisher":"Ubiquity Press, Ltd.","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,6,8]]},"DOI":"10.5334\/tohm.695","type":"journal-article","created":{"date-parts":[[2022,6,8]],"date-time":"2022-06-08T13:22:07Z","timestamp":1654694527000},"source":"Crossref","is-referenced-by-count":15,"title":["Risk of Drug-induced Movement Disorders with Newer Antipsychotic Agents"],"prefix":"10.5334","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4428-1820","authenticated-orcid":false,"given":"George T.","family":"Kannarkat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2840-4763","authenticated-orcid":false,"given":"Stanley N.","family":"Caroff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1950-9128","authenticated-orcid":false,"given":"James F.","family":"Morley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3285","reference":[{"key":"key20220608092203_B1","first-page":"1","article-title":"Differentiating tardive dyskinesia: a video-based review of antipsychotic-induced movement disorders in clinical practice","year":"2020","journal-title":"CNS Spectr"},{"key":"key20220608092203_B2","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/S1474-4422(19)30152-8","article-title":"Recent developments in drug-induced movement disorders: a mixed picture","volume":"18","year":"2019","journal-title":"Lancet Neurol"},{"key":"key20220608092203_B3","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.psc.2016.04.003","article-title":"Drug-Induced Extrapyramidal Syndromes: Implications for Contemporary Practice","volume":"39","year":"2016","journal-title":"Psychiatr. Clin. North Am"},{"key":"key20220608092203_B4","doi-asserted-by":"crossref","first-page":"e264","DOI":"10.4088\/JCP.16r10832","article-title":"Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-Analysis","volume":"78","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B5","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1176\/appi.ajp.161.3.414","article-title":"Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies","volume":"161","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000112883","article-title":"Atypical antipsychotics: CATIE study, drug-induced movement disorder and resulting iatrogenic psychiatric-like symptoms, supersensitivity rebound psychosis and withdrawal discontinuation syndromes","volume":"77","year":"2008","journal-title":"Psychother. Psychosom"},{"key":"key20220608092203_B7","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/jpet.114.213793","article-title":"Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator","volume":"350","year":"2014","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"key20220608092203_B8","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000500227","article-title":"Inhibition of Recombinant Human Acetylcholinesterase Activity by Antipsychotics","volume":"104","year":"2019","journal-title":"Pharmacology"},{"key":"key20220608092203_B9","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1176\/appi.ajp.2015.14101275","article-title":"Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial","volume":"172","year":"2015","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B10","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.schres.2015.01.038","article-title":"A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia","volume":"164","year":"2015","journal-title":"Schizophr. Res"},{"key":"key20220608092203_B11","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1111\/pcn.12654","article-title":"Long-term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52-week, open-label study","volume":"72","year":"2018","journal-title":"Psychiatry Clin. Neurosci"},{"key":"key20220608092203_B12","first-page":"6108","article-title":"Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants","volume":"76","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B13","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1111\/pcn.12682","article-title":"Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia in Japan: A 6-week, randomized, double-blind, placebo-controlled study","volume":"72","year":"2018","journal-title":"Psychiatry Clin. Neurosci"},{"key":"key20220608092203_B14","first-page":"11","article-title":"Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study","volume":"20","year":"2016","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"key20220608092203_B15","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.2147\/NDT.S176676","article-title":"Comparison of the efficacy and safety of 4 and 2 mg\/day brexpiprazole for acute schizophrenia: a meta-analysis of double-blind, randomized placebo-controlled trials","volume":"14","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"key20220608092203_B16","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.4088\/JCP.14m09689","article-title":"Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study","volume":"76","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B17","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/YIC.0000000000000140","article-title":"The effect of brexpiprazole in adult outpatients with early-episode schizophrenia: an exploratory study","volume":"31","year":"2016","journal-title":"Int. Clin. Psychopharmacol"},{"key":"key20220608092203_B18","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1093\/ijnp\/pyy002","article-title":"A Long-Term, Open-Label Study to Evaluate the Safety and Tolerability of Brexpiprazole as Maintenance Treatment in Adults with Schizophrenia","volume":"21","year":"2018","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"key20220608092203_B19","first-page":"56","article-title":"Copulatory Dyskinesia: Pathognomonic Manifestation of Tardive Dyskinesia","volume":"10","journal-title":"Tremor Hyperkinetic Mov"},{"key":"key20220608092203_B20","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.parkreldis.2019.11.013","article-title":"Severe parkinsonism caused by brexpiprazole: A case report","volume":"69","year":"2019","journal-title":"Parkinsonism Relat. Disord"},{"key":"key20220608092203_B21","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/JCP.0000000000001127","article-title":"Successful Use of Brexpiprazole for Parkinson\u2019s Disease Psychosis Without Adverse Effects: A Case Report","volume":"39","year":"2019","journal-title":"J. Clin. Psychopharmacol"},{"key":"key20220608092203_B22","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/YIC.0000000000000123","article-title":"The effect of brexpiprazole (OPC-34712) and aripiprazole in adult patients with acute schizophrenia: results from a randomized, exploratory study","volume":"31","year":"2016","journal-title":"Int. Clin. Psychopharmacol"},{"key":"key20220608092203_B23","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1017\/S1092852918001086","article-title":"Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians\u2019 choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study","volume":"24","year":"2019","journal-title":"CNS Spectr"},{"key":"key20220608092203_B24","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00213-020-05472-5","article-title":"Aripiprazole vs. brexpiprazole for acute schizophrenia: a systematic review and network meta-analysis","volume":"237","year":"2020","journal-title":"Psychopharmacology (Berl.)"},{"key":"key20220608092203_B25","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/JCP.0000000000000665","article-title":"Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm","volume":"37","year":"2017","journal-title":"J. Clin. Psychopharmacol"},{"key":"key20220608092203_B26","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1111\/ijcp.12752","article-title":"The ABC\u2019s of dopamine receptor partial agonists \u2013 aripiprazole, brexpiprazole and cariprazine: the 15-min challenge to sort these agents out","volume":"69","year":"2015","journal-title":"Int. J. Clin. Pract"},{"key":"key20220608092203_B27","doi-asserted-by":"crossref","first-page":"971","DOI":"10.12740\/PP\/OnlineFirst\/80710","article-title":"Cariprazine \u2013 a novel antipsychotic drug and its place in the treatment of schizophrenia","volume":"52","year":"2018","journal-title":"Psychiatr. Pol"},{"key":"key20220608092203_B28","doi-asserted-by":"crossref","first-page":"e401","DOI":"10.1038\/tp.2014.43","article-title":"Implication of dopamine D3 receptor activation in the reversion of Parkinson\u2019s disease-related motivational deficits","volume":"4","year":"2014","journal-title":"Transl. Psychiatry"},{"key":"key20220608092203_B29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1517\/17425255.2013.759211","article-title":"Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability","volume":"9","year":"2013","journal-title":"Expert Opin. Drug Metab. Toxicol"},{"key":"key20220608092203_B30","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/YIC.0000000000000110","article-title":"Cariprazine in the treatment of schizophrenia: a proof-of-concept trial","volume":"31","year":"2016","journal-title":"Int. Clin. Psychopharmacol"},{"key":"key20220608092203_B31","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.schres.2013.11.041","article-title":"An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial","volume":"152","year":"2014","journal-title":"Schizophr. Res"},{"key":"key20220608092203_B32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial","volume":"35","year":"2015","journal-title":"J. Clin. Psychopharmacol"},{"key":"key20220608092203_B33","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(17)30060-0","article-title":"Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial","volume":"389","year":"2017","journal-title":"The Lancet"},{"key":"key20220608092203_B34","doi-asserted-by":"crossref","first-page":"770592","DOI":"10.3389\/fpsyt.2021.770592","article-title":"Early Clinical Effects of Novel Partial D3\/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)","volume":"12","year":"2022","journal-title":"Front. Psychiatry"},{"key":"key20220608092203_B35","first-page":"2310","article-title":"Cariprazine in Acute Exacerbation of Schizophrenia: A Fixed-Dose, Phase 3, Randomized, Double-Blind, Placebo- and Active-Controlled Trial","volume":"76","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B36","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1186\/s12888-017-1459-z","article-title":"The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis","volume":"17","year":"2017","journal-title":"BMC Psychiatry"},{"key":"key20220608092203_B37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/JCP.0000000000000346","article-title":"Efficacy and Safety of Cariprazine in Acute Exacerbation of Schizophrenia: Results From an International, Phase III Clinical Trial","volume":"35","year":"2015","journal-title":"J. Clin. Psychopharmacol"},{"key":"key20220608092203_B38","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/YIC.0000000000000187","article-title":"Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II\/III randomized, double-blind, placebo-controlled studies","volume":"32","year":"2017","journal-title":"Int. Clin. Psychopharmacol"},{"key":"key20220608092203_B39","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2147\/NDT.S301225","article-title":"Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II\/III Studies","volume":"17","year":"2021","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"key20220608092203_B40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3389\/fpsyt.2020.00061","article-title":"Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data","volume":"11","year":"2020","journal-title":"Front. Psychiatry"},{"key":"key20220608092203_B41","first-page":"6112","article-title":"Efficacy and Safety of Adjunctive Cariprazine in Inadequate Responders to Antidepressants: A Randomized, Double-Blind, Placebo-Controlled Study in Adult Patients With Major Depressive Disorder","volume":"77","year":"2016","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/bdi.12238","article-title":"The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial","volume":"17","year":"2015","journal-title":"Bipolar Disord"},{"key":"key20220608092203_B43","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.jad.2017.08.040","article-title":"The safety and tolerability of cariprazine in patients with manic or mixed episodes associated with bipolar I disorder: A 16-week open-label study","volume":"225","year":"2018","journal-title":"J. Affect. Disord"},{"key":"key20220608092203_B44","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/YIC.0000000000000307","article-title":"Evaluation of cariprazine in the treatment of bipolar I and II depression: a randomized, double-blind, placebo-controlled, phase 2 trial","volume":"35","year":"2020","journal-title":"Int. Clin. Psychopharmacol"},{"key":"key20220608092203_B45","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.jad.2017.03.032","article-title":"Tolerability of cariprazine in the treatment of acute bipolar I mania: A pooled post hoc analysis of 3 phase II\/III studies","volume":"215","year":"2017","journal-title":"J. Affect. Disord"},{"key":"key20220608092203_B46","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jad.2021.03.076","article-title":"Cariprazine and akathisia, restlessness, and extrapyramidal symptoms in patients with bipolar depression","volume":"288","year":"2021","journal-title":"J. Affect. Disord"},{"key":"key20220608092203_B47","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1007\/s40263-016-0382-z","article-title":"Tolerability and Safety Profile of Cariprazine in Treating Psychotic Disorders, Bipolar Disorder and Major Depressive Disorder: A Systematic Review with Meta-Analysis of Randomized Controlled Trials","volume":"30","year":"2016","journal-title":"CNS Drugs"},{"key":"key20220608092203_B48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/s12888-021-03220-3","article-title":"Efficacy and tolerability of atypical antipsychotics for acute bipolar depression: a network meta-analysis","volume":"21","year":"2021","journal-title":"BMC Psychiatry"},{"key":"key20220608092203_B49","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s40265-020-01271-6","article-title":"Lumateperone: First Approval","volume":"80","year":"2020","journal-title":"Drugs"},{"key":"key20220608092203_B50","first-page":"32","article-title":"Lumateperone for the Treatment of Schizophrenia","volume":"50","year":"2020","journal-title":"Psychopharmacol. Bull"},{"key":"key20220608092203_B51","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.biopsych.2015.08.026","article-title":"ITI-007 for the Treatment of Schizophrenia: A 4-Week Randomized, Double-Blind, Controlled Trial","volume":"79","year":"2016","journal-title":"Biol. Psychiatry"},{"key":"key20220608092203_B52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1001\/jamapsychiatry.2019.4379","article-title":"Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial","volume":"77","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"key20220608092203_B53","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1017\/S1092852919000245","article-title":"30 Lumateperone (ITI-007) for the Treatment of Schizophrenia: Overview of Placebo-Controlled Clinical Trials and an Open-label Safety Switching Study","volume":"24","year":"2019","journal-title":"CNS Spectr"},{"key":"key20220608092203_B54","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/YIC.0000000000000371","article-title":"Safety and tolerability of lumateperone for the treatment of schizophrenia: a pooled analysis of late-phase placebo- and active-controlled clinical trials","volume":"36","year":"2021","journal-title":"Int. Clin. Psychopharmacol"},{"key":"key20220608092203_B55","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1176\/appi.ajp.2021.20091339","article-title":"Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial","volume":"178","year":"2021","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B56","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.euroneuro.2019.06.008","article-title":"Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone","volume":"29","year":"2019","journal-title":"Eur. Neuropsychopharmacol"},{"key":"key20220608092203_B57","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s00213-012-2838-2","article-title":"Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study","volume":"225","year":"2013","journal-title":"Psychopharmacology (Berl.)"},{"key":"key20220608092203_B58","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jpsychires.2013.01.020","article-title":"Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study","volume":"47","year":"2013","journal-title":"J. Psychiatr. Res"},{"key":"key20220608092203_B59","first-page":"5562","article-title":"Effectiveness of Lurasidone for Patients With Schizophrenia Following 6 Weeks of Acute Treatment With Lurasidone, Olanzapine, or Placebo: A 6-Month, Open-Label, Extension Study","volume":"74","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B60","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/0269881115620460","article-title":"A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia","volume":"30","year":"2016","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"key20220608092203_B61","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1176\/appi.ajp.2013.13070984","article-title":"Lurasidone Monotherapy in the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"171","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B62","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1176\/appi.ajp.2013.13070985","article-title":"Lurasidone as Adjunctive Therapy With Lithium or Valproate for the Treatment of Bipolar I Depression: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"171","year":"2014","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B63","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.jpsychires.2016.03.012","article-title":"Lurasidone adjunctive with lithium or valproate for bipolar depression: A placebo-controlled trial utilizing prospective and retrospective enrolment cohorts","volume":"78","year":"2016","journal-title":"J. Psychiatr. Res"},{"key":"key20220608092203_B64","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1176\/appi.ajp.2015.15060770","article-title":"Lurasidone for the Treatment of Major Depressive Disorder With Mixed Features: A Randomized, Double-Blind, Placebo-Controlled Study","volume":"173","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s40345-021-00230-8","article-title":"Lurasidone in the long-term treatment of Japanese patients with bipolar I disorder: a 52 week open label study","volume":"9","year":"2021","journal-title":"Int. J. Bipolar Disord"},{"key":"key20220608092203_B66","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/YIC.0b013e32835281ef","article-title":"Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study","volume":"27","year":"2012","journal-title":"Int. Clin. Psychopharmacol"},{"key":"key20220608092203_B67","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1017\/S109285291300093X","article-title":"Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study","volume":"19","year":"2014","journal-title":"CNS Spectr"},{"key":"key20220608092203_B68","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1002\/npr2.12131","article-title":"Efficacy, tolerability, and safety of lurasidone for acute schizophrenia: A systematic review and network meta-analysis of phase 3 trials in Japan","volume":"40","year":"2020","journal-title":"Neuropsychopharmacol. Rep"},{"key":"key20220608092203_B69","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/da.22479","article-title":"Lurasidone in the Long-Term Treatment of Patients with Bipolar Disorder: A 24-Week Open-Label Extension Study","volume":"33","year":"2016","journal-title":"Depress. Anxiety"},{"key":"key20220608092203_B70","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jad.2020.12.005","article-title":"Lurasidone in the Long-Term Treatment of Bipolar I Depression: A 28-week Open Label Extension Study","volume":"281","year":"2021","journal-title":"J. Affect. Disord"},{"key":"key20220608092203_B71","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.euroneuro.2017.06.013","article-title":"Lurasidone in combination with lithium or valproate for the maintenance treatment of bipolar I disorder","volume":"27","year":"2017","journal-title":"Eur. Neuropsychopharmacol"},{"key":"key20220608092203_B72","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1002\/mdc3.12812","article-title":"Lurasidone-Induced Tardive Syndrome","volume":"6","year":"2019","journal-title":"Mov. Disord. Clin. Pract"},{"key":"key20220608092203_B73","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1097\/JCP.0000000000001112","article-title":"Consumption of Aspartame Associated with Tardive Dyskinesia: New Observation","volume":"39","year":"2019","journal-title":"J. Clin. Psychopharmacol"},{"key":"key20220608092203_B74","doi-asserted-by":"crossref","first-page":"e553","DOI":"10.4088\/JCP.16cr11157","article-title":"Lurasidone \u2013 Induced Rabbit Syndrome: A Case Report","volume":"78","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B75","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/0091217420943786","article-title":"A missed case of lurasidone induced laryngospasm: A case study and overview of extrapyramidal symptom identification and treatment","volume":"56","year":"2021","journal-title":"Int. J. Psychiatry Med"},{"key":"key20220608092203_B76","doi-asserted-by":"crossref","first-page":"192","DOI":"10.4103\/IJPSYM.IJPSYM_274_18","article-title":"Lurasidone-induced Parkinsonism and Hyperprolactinemia","volume":"41","year":"2019","journal-title":"Indian J. Psychol. Med"},{"key":"key20220608092203_B77","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1176\/appi.ajp.2011.10060907","article-title":"Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study","volume":"168","year":"2011","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B78","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2013.01.009","article-title":"Efficacy and safety of lurasidone 80mg\/day and 160mg\/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial","volume":"145","year":"2013","journal-title":"Schizophr. Res"},{"key":"key20220608092203_B79","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.schres.2013.03.013","article-title":"Effectiveness of lurasidone vs. quetiapine XR for relapse prevention in schizophrenia: A 12-month, double-blind, noninferiority study","volume":"147","year":"2013","journal-title":"Schizophr. Res"},{"key":"key20220608092203_B80","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/npr2.12137","article-title":"Lurasidone, olanzapine, and quetiapine extended-release for bipolar depression: A systematic review and network meta-analysis of phase 3 trials in Japan","volume":"40","year":"2020","journal-title":"Neuropsychopharmacol. Rep"},{"key":"key20220608092203_B81","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.schres.2011.04.008","article-title":"Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia or schizoaffective disorder","volume":"132","year":"2011","journal-title":"Schizophr. Res"},{"key":"key20220608092203_B82","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","article-title":"Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis","volume":"382","year":"2013","journal-title":"The Lancet"},{"key":"key20220608092203_B83","first-page":"586","article-title":"Lurasidone compared to other atypical antipsychotic monotherapies for bipolar depression: A systematic review and network meta-analysis","volume":"19","year":"2018","journal-title":"World J. Biol. Psychiatry Off. J. World Fed. Soc. Biol. Psychiatry"},{"key":"key20220608092203_B84","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.schres.2012.07.029","article-title":"Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg\/day, but does not enhance efficacy of haloperidol, 2mg\/day: Comparison with reference dose risperidone, 6mg\/day","volume":"141","year":"2012","journal-title":"Schizophr. Res"},{"key":"key20220608092203_B85","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1124\/jpet.105.097006","article-title":"Pharmacological and Behavioral Profile of N-(4-Fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N\u2032-(4-(2-methylpropyloxy)phenylmethyl) Carbamide (2R,3R)-Dihydroxybutanedioate (2:1) (ACP-103), a Novel 5-Hydroxytryptamine2A Receptor Inverse Agonist","volume":"317","year":"2006","journal-title":"J. Pharmacol. Exp. Ther"},{"key":"key20220608092203_B86","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1038\/npp.2009.176","article-title":"Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson\u2019s Disease Psychosis","volume":"35","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"key20220608092203_B87","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/S0140-6736(13)62106-6","article-title":"Pimavanserin for patients with Parkinson\u2019s disease psychosis: a randomised, placebo-controlled phase 3 trial","volume":"383","year":"2014","journal-title":"The Lancet"},{"key":"key20220608092203_B88","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2215-0366(21)00386-2","article-title":"Pimavanserin for negative symptoms of schizophrenia: results from the ADVANCE phase 2 randomised, placebo-controlled trial in North America and Europe","volume":"9","year":"2022","journal-title":"Lancet Psychiatry"},{"key":"key20220608092203_B89","unstructured":"ACADIA Pharmaceuticals Inc. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia; 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02970292"},{"key":"key20220608092203_B90","unstructured":"ACADIA Pharmaceuticals Inc. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia; 2020. https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02970305"},{"key":"key20220608092203_B91","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1016\/j.neubiorev.2021.11.032","article-title":"New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics","volume":"132","year":"2022","journal-title":"Neurosci. Biobehav. Rev"},{"key":"key20220608092203_B92","article-title":"Olanzapine\/Samidorphan: New Drug Approved for Treating Bipolar I Disorder and Schizophrenia","year":"2022","journal-title":"Ann. Pharmacother"},{"key":"key20220608092203_B93","first-page":"5960","article-title":"Efficacy and Safety of a Combination of Olanzapine and Samidorphan in Adult Patients With an Acute Exacerbation of Schizophrenia: Outcomes From the Randomized, Phase 3 ENLIGHTEN-1 Study","volume":"81","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B94","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.1176\/appi.ajp.2020.19121279","article-title":"Effects of Olanzapine Combined With Samidorphan on Weight Gain in Schizophrenia: A 24-Week Phase 3 Study","volume":"177","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B95","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1016\/j.clinthera.2018.09.002","article-title":"Pharmacokinetics and Short-term Safety of ALKS 3831, a Fixed-dose Combination of Olanzapine and Samidorphan, in Adult Subjects with Schizophrenia","volume":"40","year":"2018","journal-title":"Clin. Ther"},{"key":"key20220608092203_B96","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/appi.ajp.2018.18030280","article-title":"Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia","volume":"176","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B97","first-page":"13176","article-title":"Olanzapine Plus Samidorphan (ALKS 3831) in Schizophrenia and Comorbid Alcohol Use Disorder: A Phase 2, Randomized Clinical Trial","volume":"81","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B98","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1017\/S1092852920001376","article-title":"Long-term safety and durability of effect with a combination of olanzapine and samidorphan in patients with schizophrenia: results from a 1-year open-label extension study","volume":"26","year":"2021","journal-title":"CNS Spectr"},{"key":"key20220608092203_B99","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.schbul.a007076","article-title":"Poor Antipsychotic Adherence Among Patients With Schizophrenia: Medication and Patient Factors","volume":"30","year":"2004","journal-title":"Schizophr. Bull"},{"key":"key20220608092203_B100","doi-asserted-by":"crossref","first-page":"361","DOI":"10.9758\/cpn.2018.16.4.361","article-title":"Comparative efficacy and safety of long-Acting injectable and oral second-generation antipsychotics for the treatment of schizophrenia: A systematic review and meta-Analysis","volume":"16","year":"2018","journal-title":"Clin. Psychopharmacol. Neurosci"},{"key":"key20220608092203_B101","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2010.11.020","article-title":"Oral versus depot antipsychotic drugs for schizophrenia\u2014A critical systematic review and meta-analysis of randomised long-term trials","volume":"127","year":"2011","journal-title":"Schizophr. Res"},{"key":"key20220608092203_B102","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jpsychires.2020.06.013","article-title":"Preliminary efficacy and tolerability profiles of first versus second-generation Long-Acting Injectable Antipsychotics in schizophrenia: A systematic review and meta-analysis","volume":"129","year":"2020","journal-title":"J. Psychiatr. Res"},{"key":"key20220608092203_B103","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.schres.2021.11.030","article-title":"Long-term efficacy and safety of once-monthly Risperidone ISM\u00ae in the treatment of schizophrenia: Results from a 12-month open-label extension study","volume":"239","year":"2022","journal-title":"Schizophr. Res"},{"key":"key20220608092203_B104","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/S0006-3223(00)00364-4","article-title":"102. Kinetics and safety of a novel risperidone depot formulation","volume":"47","year":"2000","journal-title":"Biol. Psychiatry"},{"key":"key20220608092203_B105","doi-asserted-by":"crossref","first-page":"7","DOI":"10.12740\/PP\/64581","article-title":"Paliperidone palmitate: effectiveness, safety, and the use for treatment of schizophrenia","volume":"51","year":"2017","journal-title":"Psychiatr. Pol"},{"key":"key20220608092203_B106","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1586\/ern.10.143","article-title":"Risperidone long-acting injectable (Risperdal Consta\u00ae) for maintenance treatment in patients with bipolar disorder","volume":"10","year":"2010","journal-title":"Expert Rev. Neurother"},{"key":"key20220608092203_B107","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/YIC.0000000000000203","article-title":"A phase II study to evaluate the pharmacokinetics, safety, and tolerability of Risperidone ISM multiple intramuscular injections once every 4 weeks in patients with schizophrenia","volume":"33","year":"2018","journal-title":"Int. Clin. Psychopharmacol"},{"key":"key20220608092203_B108","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1097\/YIC.0b013e328343ba60","article-title":"Long-term efficacy of risperidone long-acting injectable in bipolar disorder with psychotic features: a prospective study of 3-year outcomes","volume":"26","year":"2011","journal-title":"Int. Clin. Psychopharmacol"},{"key":"key20220608092203_B109","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1177\/0269881116655978","article-title":"Risperidone long-acting injectable in the treatment of treatment-resistant schizophrenia with dopamine supersensitivity psychosis: Results of a 2-year prospective study, including an additional 1-year follow-up","volume":"30","year":"2016","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"key20220608092203_B110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.schres.2005.03.015","article-title":"An assessment of emergent tardive dyskinesia and existing dyskinesia in patients receiving long-acting, injectable risperidone: results from a long-term study","volume":"77","year":"2005","journal-title":"Schizophr. Res"},{"key":"key20220608092203_B111","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2174\/157488612800492807","article-title":"Atypical presentation of tardive dyskinesia associated with risperidone long-acting injection as maintenance treatment in bipolar affective disorder: a case report","volume":"7","year":"2012","journal-title":"Curr. Drug Saf"},{"key":"key20220608092203_B112","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.schres.2016.11.010","article-title":"Does formulation matter? A systematic review and meta-analysis of oral versus long-acting antipsychotic studies","volume":"183","year":"2017","journal-title":"Schizophr. Res"},{"key":"key20220608092203_B113","first-page":"CD004161","article-title":"Risperidone (depot) for schizophrenia","volume":"4","year":"2016","journal-title":"Cochrane Database Syst. Rev"},{"key":"key20220608092203_B114","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1038\/npp.2010.79","article-title":"A Controlled, Evidence-Based Trial of Paliperidone Palmitate, A Long-Acting Injectable Antipsychotic, in Schizophrenia","volume":"35","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"key20220608092203_B115","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1017\/S1461145709990988","article-title":"Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study","volume":"13","year":"2010","journal-title":"Int. J. Neuropsychopharmacol"},{"key":"key20220608092203_B116","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1001\/jamapsychiatry.2015.0241","article-title":"Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia: A Randomized Clinical Trial","volume":"72","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"key20220608092203_B117","doi-asserted-by":"crossref","first-page":"205","DOI":"10.2147\/NDT.S139633","article-title":"Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review","volume":"14","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"key20220608092203_B118","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.2147\/NDT.S131224","article-title":"Safety and efficacy of paliperidone palmitate 1-month formulation in Chinese patients with schizophrenia: a 25-week, open-label, multicenter, Phase IV study","volume":"13","year":"2017","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"key20220608092203_B119","first-page":"1381","article-title":"Incidence and time course of extrapyramidal symptoms with oral and long-acting injectable paliperidone: a posthoc pooled analysis of seven randomized controlled studies","volume":"9","year":"2013","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"key20220608092203_B120","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1111\/ijcp.12493","article-title":"Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases","volume":"68","year":"2014","journal-title":"Int. J. Clin. Pract"},{"key":"key20220608092203_B121","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.2147\/NDT.S176478","article-title":"Long-lasting extrapyramidal symptoms after multiple injections of paliperidone palmitate to treat schizophrenia","volume":"14","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat"},{"key":"key20220608092203_B122","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.euroneuro.2016.04.006","article-title":"A case of tardive dystonia associated with long-acting injectable paliperidone palmitate","volume":"26","year":"2016","journal-title":"Eur. Neuropsychopharmacol"},{"key":"key20220608092203_B123","first-page":"213.e5\u20137","article-title":"A case of paliperidone-palmitate-induced tardive dyskinesia","volume":"35","year":"2013","journal-title":"Gen. Hosp. Psychiatry"},{"key":"key20220608092203_B124","first-page":"288","article-title":"Five Month-Persistent Extrapyramidal Symptoms following a Single Injection of Paliperidone Palmitate: A Case Report","volume":"15","year":"2017","journal-title":"Clin. Psychopharmacol. Neurosci. Off. Sci. J. Korean Coll. Neuropsychopharmacol"},{"key":"key20220608092203_B125","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.pnpbp.2011.02.001","article-title":"A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia","volume":"35","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"key20220608092203_B126","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.pnpbp.2010.11.008","article-title":"A double-blind study of paliperidone palmitate and risperidone long-acting injectable in adults with schizophrenia","volume":"35","year":"2011","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"key20220608092203_B127","first-page":"CD008296","article-title":"Paliperidone palmitate for schizophrenia","year":"2012","journal-title":"Cochrane Database Syst. Rev"},{"key":"key20220608092203_B128","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/JCP.0000000000000993","article-title":"Comparison of Paliperidone Palmitate and Second-Generation Oral Antipsychotics in Terms of Medication Adherence, Side Effects, and Quality of Life","volume":"39","year":"2019","journal-title":"J. Clin. Psychopharmacol"},{"key":"key20220608092203_B129","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1017\/S1092852916000444","article-title":"Once-monthly paliperidone palmitate compared with conventional and atypical daily oral antipsychotic treatment in patients with schizophrenia","volume":"21","year":"2016","journal-title":"CNS Spectr"},{"key":"key20220608092203_B130","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.schres.2015.07.007","article-title":"Qualify: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia","volume":"168","year":"2015","journal-title":"Schizophr. Res"},{"key":"key20220608092203_B131","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1586\/17512433.2016.1121809","article-title":"Aripiprazole long-acting injectable formulations for schizophrenia: aripiprazole monohydrate and aripiprazole lauroxil","volume":"9","year":"2016","journal-title":"Expert Rev. Clin. Pharmacol"},{"key":"key20220608092203_B132","doi-asserted-by":"crossref","first-page":"279","DOI":"10.3390\/neurolint13030029","article-title":"Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: A Comprehensive Review","volume":"13","year":"2021","journal-title":"Neurol. Int"},{"key":"key20220608092203_B133","doi-asserted-by":"crossref","first-page":"18488","DOI":"10.1073\/pnas.1104807108","article-title":"Discovery of \u03b2-arrestin-biased dopamine D2 ligands for probing signal transduction pathways essential for antipsychotic efficacy","volume":"108","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"key":"key20220608092203_B134","first-page":"1347","article-title":"Aripiprazole Once-Monthly in the Acute Treatment of Schizophrenia: Findings From a 12-Week, Randomized, Double-Blind, Placebo-Controlled Study","volume":"75","year":"2014","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B135","first-page":"16764","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial of Aripiprazole Lauroxil in Acute Exacerbation of Schizophrenia","volume":"76","year":"2015","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B136","doi-asserted-by":"crossref","first-page":"617","DOI":"10.4088\/JCP.11m07530","article-title":"Aripiprazole intramuscular depot as maintenance treatment in patients with schizophrenia: a 52-week, multicenter, randomized, double-blind, placebo-controlled study","volume":"73","year":"2012","journal-title":"J. Clin. Psychiatry"},{"key":"key20220608092203_B137","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1517\/17425255.2014.908185","article-title":"Asenapine review, part I: chemistry, receptor affinity profile, pharmacokinetics and metabolism","volume":"10","year":"2014","journal-title":"Expert Opin. Drug Metab. Toxicol"},{"key":"key20220608092203_B138","article-title":"Asenapine: an atypical antipsychotic with atypical formulations","volume":"11","year":"2021","journal-title":"Ther. Adv. Psychopharmacol"},{"key":"key20220608092203_B139","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1176\/appi.ajp.2017.16040419","article-title":"Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder","volume":"175","year":"2018","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B140","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s11920-021-01298-w","article-title":"New Antipsychotic Medications in the Last Decade","volume":"23","year":"2021","journal-title":"Curr. Psychiatry Rep"},{"key":"key20220608092203_B141","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12991-015-0053-3","article-title":"Revisiting loxapine: a systematic review","volume":"14","year":"2015","journal-title":"Ann. Gen. Psychiatry"},{"key":"key20220608092203_B142","first-page":"92","article-title":"Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia","volume":"13","year":"2021","journal-title":"ACS Med. Chem. Lett"},{"key":"key20220608092203_B143","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1911772","article-title":"A Non\u2013D2-Receptor-Binding Drug for the Treatment of Schizophrenia","volume":"382","year":"2020","journal-title":"N. Engl. J. Med"},{"key":"key20220608092203_B144","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1176\/appi.ajp.2017.17010122","article-title":"Efficacy and Safety of MIN-101: A 12-Week Randomized, Double-Blind, Placebo-Controlled Trial of a New Drug in Development for the Treatment of Negative Symptoms in Schizophrenia","volume":"174","year":"2017","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B145","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1176\/appi.ajp.2008.06091591","article-title":"Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia","volume":"165","year":"2008","journal-title":"Am. J. Psychiatry"},{"key":"key20220608092203_B146","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1038\/sj.bjp.0702201","article-title":"Functional effects of the muscarinic receptor agonist, xanomeline, at 5-HT1 and 5-HT2 receptors","volume":"125","year":"1998","journal-title":"Br. J. Pharmacol"},{"key":"key20220608092203_B147","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1056\/NEJMoa2017015","article-title":"Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia","volume":"384","year":"2021","journal-title":"N. Engl. J. Med"},{"key":"key20220608092203_B148","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/S0140-6736(19)31135-3","article-title":"Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi-episode schizophrenia: a systematic review and network meta-analysis","volume":"394","year":"2019","journal-title":"Lancet Lond. Engl"},{"key":"key20220608092203_B149","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1016\/S0140-6736(21)01997-8","article-title":"Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis","volume":"399","year":"2022","journal-title":"Lancet Lond. Engl"},{"key":"key20220608092203_B150","first-page":"e109","article-title":"Off-label use of antipsychotic medications in Medicaid","volume":"18","year":"2012","journal-title":"Am. J. Manag. Care"},{"key":"key20220608092203_B151","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1176\/ps.2009.60.9.1175","article-title":"Off-label use of antipsychotic medications in the department of Veterans Affairs health care system","volume":"60","year":"2009","journal-title":"Psychiatr. Serv. Wash. DC"},{"key":"key20220608092203_B152","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1002\/phar.1910","article-title":"Analysis of the Appropriateness of Off-Label Antipsychotic Use for Mental Health Indications in a Veteran Population","volume":"37","year":"2017","journal-title":"Pharmacotherapy"},{"key":"key20220608092203_B153","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.2147\/NDT.S159704","article-title":"Cariprazine for acute and maintenance treatment of adults with schizophrenia: an evidence-based review and place in therapy","volume":"14","year":"2018","journal-title":"Neuropsychiatr. Dis. Treat"}],"container-title":["Tremor and Other Hyperkinetic Movements"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/doi.org\/10.5334\/tohm.695","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,11]],"date-time":"2022-07-11T09:25:54Z","timestamp":1657531554000},"score":1,"resource":{"primary":{"URL":"https:\/\/tremorjournal.org\/articles\/10.5334\/tohm.695\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":153,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,6,8]]}},"alternative-id":["10.5334\/tohm.695"],"URL":"https:\/\/doi.org\/10.5334\/tohm.695","relation":{},"ISSN":["2160-8288"],"issn-type":[{"value":"2160-8288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022]]},"article-number":"19"}}